Cancer Family
Malignant Bone Marrow Neoplasm
CI-CAN-00000226Explore in graph →
1,034 active trials28 approved drugs633 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000226Explore in graph →
Clinical trials
4,609 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (799)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02172872 | "InDACtion" vs "3+7" Induction in AML | unknown | Phase 3 | 606 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Feb 15, 2023 | clinicaltrials |
| NCT02338479 | Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies | unknown | — | 340 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 |
| Feb 8, 2023 |
| clinicaltrials |
| NCT05717634 | Endometrial Changes in Breast Cancer Women. | unknown | — | 829 | Regina Elena Cancer InstituteOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05665075 | Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia | unknown | Phase 1 | 19 | Zhejiang UniversityOTHER | 1 | Jan 3, 2023 | clinicaltrials |
| NCT05665114 | Natural Killer(NK) Cell Therapy in r/r AML | unknown | Phase 1 | 18 | Zhejiang UniversityOTHER | 1 | Jan 3, 2023 | clinicaltrials |
| NCT03709017 | Iclusig PMS in CML or Ph+ALL Patients | unknown | — | 50 | Korea Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 7, 2022 | clinicaltrials |
| NCT05638763 | Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia | unknown | Phase 2 | 15 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT05632874 | The Effect of Relaxing Breathing Exercise Applied to Patients Before Bone Marrow Biopsy on Vital Signs, Pain and Anxiety Levels | unknown | N/A | 72 | Uskudar UniversityOTHER | 1 | Dec 1, 2022 | clinicaltrials |
| NCT05291390 | Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) | unknown | Phase 2 | 200 | Armaceutica, Inc.INDUSTRY | 1 | Nov 29, 2022 | clinicaltrials |
| NCT05519384 | Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia | unknown | Early Phase 1 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 28, 2022 | clinicaltrials |
| NCT04913922 | Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML(AARON) | unknown | Phase 2 | 30 | Ludwig-Maximilians - University of MunichOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT03855371 | Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS(PANDA-T0) | unknown | Phase 1 | 5 | Ruijin HospitalOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT05596968 | The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT | unknown | — | 37 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05596981 | The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT | unknown | — | 60 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05497310 | Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL | unknown | Phase 1 / Phase 2 | 15 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT05587088 | Evaluation of the Safety and Efficacy of Esperanza Extract (PA001)(PA001) | unknown | Phase 1 / Phase 2 | 82 | Hospital Universitario San IgnacioOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT05577611 | An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | unknown | Phase 1 | 57 | Zhongnan HospitalOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT03825367 | Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML | unknown | Phase 1 / Phase 2 | 13 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT03697707 | Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia(ADVANCE-II) | unknown | Phase 2 | 20 | MendusINDUSTRY | 5 | Oct 10, 2022 | clinicaltrials |
| NCT03169296 | Clinical and Genomic Registry of MDS in Asia | unknown | — | 2,600 | The University of Hong KongOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT03624270 | Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia | unknown | Phase 2 | 60 | The University of Hong KongOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT04226768 | Enhanced Palliative Care in MDS and AML | unknown | N/A | 90 | The University of Hong KongOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT04251754 | The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project | unknown | — | 1,000 | The University of Hong KongOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT04689815 | Oral Arsenic Trioxide for NPM1-mutated AML | unknown | Phase 2 | 50 | The University of Hong KongOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT05566535 | Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical Practice(QoL-PV-R) | unknown | — | 32 | Multinational Center for Quality of Life Research, RussiaOTHER | 0 | Oct 4, 2022 | clinicaltrials |
| NCT04033627 | TCDαβ/CD45RA Haploidentical Transplantation in Children With Leukemia | unknown | N/A | 30 | Shanghai Children's Medical CenterOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT05543161 | "Peripheral Blood Dipeptidylpeptidase IV (CD26) Positive Leukemic Stem Cells in Chronic Myeloid Leukemia as a Diagnostic Marker" | unknown | — | 50 | Sohag UniversityOTHER | 1 | Sep 16, 2022 | clinicaltrials |
| NCT04248595 | Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML | unknown | Phase 2 | 100 | Ge ZhengOTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT05513131 | Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAML | unknown | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT05512104 | Clinical Characters and Outcome of Acute Myeloid Leukemia Patients on Correlation to CD200 and CD56 Expression | unknown | — | 51 | Assiut UniversityOTHER | 0 | Aug 23, 2022 | clinicaltrials |
| NCT05488132 | Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) | unknown | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT03173612 | The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia | unknown | N/A | 132 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT05311943 | Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs. | unknown | Phase 3 | 40 | Shenzhen Second People's HospitalOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT04155411 | Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP | unknown | Phase 4 | 65 | Shenzhen Second People's HospitalOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT05473221 | Evaluate the Safety and Efficacy of CD33 CAR-T in Patients With R/R AML | unknown | Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT05467202 | Evaluate the Safety and Efficacy of CLL1 CAR-T in Patients With R/R AML | unknown | Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT05467254 | Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML | unknown | Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT05463640 | Evaluate the Safety and Efficacy of ADGRE2 CAR-T in Patients With R/R AML | unknown | Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT04632316 | A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 33 | Glycostem Therapeutics BVINDUSTRY | 5 | Jun 21, 2022 | clinicaltrials |
| NCT05404516 | Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML | unknown | Phase 2 | 88 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT05382390 | Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial | unknown | Phase 3 | 130 | Huihan WangOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT05383014 | FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia. | unknown | — | 82 | Assiut UniversityOTHER | 0 | May 19, 2022 | clinicaltrials |
| NCT04886206 | Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation(ILDA) | unknown | Phase 1 | 12 | Nantes University HospitalOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT05362942 | Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia | unknown | Phase 2 | 52 | Beijing 302 HospitalOTHER | 0 | May 5, 2022 | clinicaltrials |
| NCT04709458 | Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis | unknown | Phase 1 | 10 | Taiga Biotechnologies, Inc.INDUSTRY | 2 | May 3, 2022 | clinicaltrials |
| NCT05154474 | Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy(SPACE2) | unknown | — | 150 | WepromOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT05330364 | Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia | unknown | Phase 2 | 31 | Ge ZhengOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT05353205 | A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. | unknown | Phase 4 | 200 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 29, 2022 | clinicaltrials |
| NCT05053425 | Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML | unknown | N/A | 30 | LanZhou UniversityOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT05042531 | Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia | unknown | N/A | 30 | LanZhou UniversityOTHER | 1 | Apr 25, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Feb 15, 2023source: clinicaltrials